Clinical Trials Logo

KRAS Gene Mutation clinical trials

View clinical trials related to KRAS Gene Mutation.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03965845 Completed - Solid Tumors Clinical Trials

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Start date: June 25, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor telaglenestat (CB-839) with the CDK4/6 Inhibitor, palbociclib in participants with advanced/metastatic solid tumors.

NCT ID: NCT03829410 Completed - Clinical trials for Metastatic Colorectal Cancer

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation

Start date: May 6, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the Phase 1b/2 study is to determine the safety and efficacy of Onvansertib, administered orally, daily on Day 1-5 and Day 15-19 of each 28-day cycle, in combination with FOLFIRI + Bevacizumab, as second-line treatment in adult participants who have metastatic colorectal cancer with a Kras mutation. Participants must have histologically confirmed metastatic and unresectable disease, and previously failed treatment or be intolerant to fluoropyrimidine and oxaliplatin with or without bevacizumab.

NCT ID: NCT03750175 Completed - Clinical trials for Colorectal Cancer Metastatic

OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -

OPTIPAL-II
Start date: June 1, 2018
Phase:
Study type: Observational

The present study will investigate the feasibility and clinical value of using circulating tumor DNA as selection for anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.

NCT ID: NCT03704688 Completed - Clinical trials for Non Small Cell Lung Cancer

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

Start date: October 9, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety of the combination of ponatinib and trametinib as well as the most appropriate dosages of the combination.

NCT ID: NCT03520842 Completed - Clinical trials for Metastatic Malignant Neoplasm in the Brain

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

Start date: August 14, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well regorafenib works together with methotrexate in treating participants with metastatic non-squamous non-small cell lung cancer with tumors that harbor a KRAS mutation. Regorafenib is a targeted therapy that works on different cancer pathways to stop the growth of tumor cells and stop them from spreading. Methotrexate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving regorafenib and methotrexate together may work in treating participants with KRAS mutated non-small cell lung cancer.

NCT ID: NCT03171636 Completed - Lung Neoplasms Clinical Trials

Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients

Start date: April 2014
Phase:
Study type: Observational

The assessment of the type and frequency of EGFR and KRAS mutations in lung cancer patients, as well as clinical-prognostic correlation, are crucial in the era of targeted therapies. EGFR-activating mutations predict responsiveness to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) patients and KRAS analysis will be useful in a near future for newest target drugs. In Brazil, few data about the prevalence of EGFR and KRAS mutations is available and their knowledge would allow optimize personalized medicine.

NCT ID: NCT02964689 Completed - Lung Cancer Clinical Trials

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

Start date: April 12, 2017
Phase: Phase 1
Study type: Interventional

The aim is to determine the recommended phase 2 dose (RP2D) of binimetinib in combination with pemetrexed and cisplatin, and to demonstrate that the combination is feasible and has preliminary activity in previously untreated patients with advanced NSCLC and documented KRAS mutations.

NCT ID: NCT02818725 Completed - KRAS Gene Mutation Clinical Trials

I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations

GETUG-AFU19
Start date: June 2010
Phase: Phase 3
Study type: Interventional

OBJECTIVES OF THE TRIAL Primary objective Evaluation of efficacy in terms of progression-free survival at 9 months of the combination of intensified methotrexate, vinblastine, doxorubicin and cisplatin with or without panitumumab as first-line treatment of advanced urothelial carcinoma in patients without Harvey nor Kirsten rat sarcoma viral oncogene homolog mutations. Secondary objectives - To assess toxicity - To assess response rate - To assess overall survival - To assess time to progression - To study the correlation between response rate, time to progression, overall survival and biological parameters

NCT ID: NCT01700582 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings

Start date: April 2012
Phase:
Study type: Observational

The French National Cancer Institute (INCa) support a 28 hospital platforms network for molecular testing of cancer patients. These platforms routinely assess a panel of biomarkers in order to speed up access of French cancer patients to targeted therapies (commercially available or through clinical trials). The objective of the BIOMARKERS-France study is to describe the epidemiological, clinical and molecular characteristics of these patients and their tumors and to assess the impact of these analyzes on their treatment (ie bio-guided therapy) as well as outcomes (response rate, progression free and overall survival).